FDA Approves Drug Combination for Treating Mesothelioma
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.

This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.

WHAT Is Malignant Pleural Mesothelioma (MPM):

Malignant pleural mesothelioma (MPM) is a life-threatening cancer of the lungs’ lining caused by inhaling asbestos fibers. MPM accounts for most mesothelioma diagnoses, and most patients have an unresectable tumor at time of diagnosis.

Opdivo and Yervoy are both monoclonal antibodies that, when combined, decrease tumor growth by enhancing T-cell function.

EVALUATED IN A TRIAL:

This combination therapy was evaluated during a randomized, open-label trial in 605 patients with previously untreated unresectable MPM.

Patients received intravenous infusions of Opdivo every two weeks with intravenous infusions of Yervoy every six weeks for up to two years, or platinum-doublet chemotherapy for up to six cycles.

RESULTS OF TRIAL:

Patients who received Opdivo in combination with Yervoy survived a median of 18.1 months while patients who underwent chemotherapy survived a median of 14.1 months.

COMMON SIDE EFFECTS:

Fatigue, musculoskeletal pain, rash, diarrhoea, dyspnea, nausea, decreased appetite, cough and pruritis.

The FDA granted approval to Bristol-Myers Squibb Company.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma
S S and 6 others like this5 shares
Like
Comment
Share
V●●●n b●●●●●●j
v●●●n b●●●●●●j General Medicine
Sir ye medicine kis kam aata h
Oct 8, 2020Like